Local excision for rectal cancer-safety and efficacy challenges

Annals of Surgical Oncology

Volumn 16, Issue 8, 2009, Pages 2369-2370

  Marakis, G ^a   Demetriades, H ^a   Ziogas, D ^b   Kanellos, I ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; GENOMICS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LETTER; QUALITY OF LIFE; RECTUM CANCER; STOMACH CANCER; TREATMENT OUTCOME;

HUMANS; NEOPLASM RECURRENCE, LOCAL; RECTAL NEOPLASMS;

EID: 67650999166     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0499-0     Document Type: Letter

References (31)

1. WE Enker HT Thaler ML Cranor T Polyak 1995 Total mesorectal excision in the operative treatment of carcinoma of the rectum J Am Coll Surg 181 335 346
2. DH Roukos 2002 Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9 220 221
3. DH Roukos 2009 Personalized cancer diagnostics and therapeutics Expert Rev Mol Diagn 9 227 9
4. T Borschitz I Gockel R Kiesslich T Junginger 2008 Oncological outcome after local excision of rectal carcinomas Ann Surg Oncol 15 3101 3108
5. SH Baik WJ Lee KH Rha NK Kim SK Sohn HS Chi 2008 Robotic total mesorectal excision for rectal cancer using four robotic arms Surg Endosc 22 3 792 797
6. T Liakakos DH Roukos 2008 More controversy than ever-challenges and promises towards personalized treatment of gastric cancer Ann Surg Oncol 15 4 956 960
7. DH Roukos AM Kappas NJ Agnantis 2003 Perspectives and risks of breast-conservation therapy for breast cancer Ann Surg Oncol 10 718 721
8. M Fatouros DH Roukos I Arampatzis A Sotiriadis E Paraskevaidis AM Kappas 2005 Factors increasing local recurrence in breast-conserving surgery Expert Rev Anticancer Ther 5 4 737 745
9. DH Roukos E Lykoudis T Liakakos 2008 Genomics and challenges toward personalized breast cancer local control J Clin Oncol 26 26 4360 4361
10. E Briasoulis M Fatouros DH Roukos 2007 Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14 2691 2695
11. DH Roukos 2008 Linking contralateral breast cancer with genetics Radiother Oncol 86 139 141
12. E Briasoulis T Liakakos L Dova M Fatouros P Tsekeris DH Roukos 2006 Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer Expert Rev Anticancer Ther 6 931 939
13. DH Roukos 2008 Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery Expert Rev Mol Diagn 8 5 587 597
14. DH Roukos 2008 Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies Expert Rev Mol Diagn 8 1 29 39
15. DH Roukos E Briasoulis 2007 Individualized preventive and therapeutic management of hereditary breast ovarian cancer Nat Clin Pract Oncol 4 10 578 590
16. DH Roukos 2000 Personal genomics and genome-wide association studies: Novel discoveries but limitations for practical personalized medicine Ann Surg Oncol 16 772 773
17. M Fatouros G Baltogiannis DH Roukos 2008 The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations Ann Surg Oncol 15 1 21 33
18. DH Roukos NJ Agnanti E Paraskevaidis AM Kappas 2002 Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations Ann Surg Oncol 9 10 941 943
19. NJ Agnantis E Paraskevaidis D Roukos 2004 Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance Ann Surg Oncol 11 12 1030 1034
20. DH Roukos 2007 Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations N Engl J Med 357 15 1555 1556 author reply 1556
21. D Ziogas G Baltogiannis M Fatouros DH Roukos 2008 Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations Ann Surg 247 4 714 715
22. DH Roukos 2008 HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 358 197 author reply 198
23. DH Roukos 2008 Breast-cancer stromal cells with TP53 mutations N Engl J Med 358 15 1636 author reply 1636
24. DH Roukos 2009 Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine Expert Rev Mol Diagn 9 3 217 21
25. DH Roukos 2009 Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther 9 4 389 92
26. DH Roukos 2009 Radiation therapy for breast cancer N Engl J Med 360 13 1362 3
27. DH Roukos 2009 Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer J Clin Oncol 27 8 1337 8
28. DH Roukos 2009 Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention Expert Rev Mol Diagn 9 1 1 6
29. DH Roukos 2009 Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer Ann Surg Oncol 16 4 795 8
30. AM Kappas DH Roukos 2002 Quality of surgery determinant for the outcome of patient with gastric cancer Ann Surg Oncol 9 828 830
31. DH Roukos P Paraschou M Lorenz 2000 Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery Ann Surg Oncol 7 10 719 26